Investor Presentation: First Nine Months of 2020

41 Investor presentation First nine months of 2020 Novo Nordisk global insulin market leadership expanded to 46.9% and the global insulin volume market grew by 2.8% North America Operations Market growth: 0.2% MS: 39.6% MS gain/loss: -0.3%-p Sales growth: -22% Global Market growth: 2.8% MS: 46.9% MS gain/loss¹: 0.4%-p Sales growth: -3% International Operations Market growth: 3.8% MS: 49.7% MS gain/loss: 0.6%-p Sales growth: 10% USA Market growth: 0.2% MS: 39.5% MS gain/loss': -0.6%-p Sales growth: -23% Source: IQVIA MAT, Aug 2020 volume figures Note: Sales growth for first nine months of 2020 at constant exchange rates; Market shares are for Novo Nordisk and market growth for the total insulin market 1MS gain/loss compared with Aug 2019 reported MS EMEA: Europe, Middle East, Africa; MS: Market share; RoW: Asia Pacific; Latin America; EMEA Market growth: 2.7% MS: 47.2% MS gain/loss: 0.4%-p Sales growth: 6% ROW Market growth: 6.2% MS: 57.0% MS gain/loss: 1.1%-p Sales growth: 12% Region China Market growth: 5.1% MS: 49.5% MS gain/loss': -0.6%-p Sales growth: 14% Novo NordiskⓇ

View entire presentation